GRI Bio (GRI) Net Income (2020 - 2026)
GRI Bio (GRI) posted quarterly Net Income of -$2.0 million for Q1 2026, up 34.35% year-over-year from -$1.5 million in Q1 2025, and up 91.14% quarter-over-quarter from -$22.6 million in Q4 2025.
GRI Bio (GRI) Net Income (2020 - 2026) Analysis & Trends
GRI Bio's Net Income history runs 7 years deep, the most recent figure standing at -$2.0 million for Q1 2026.
- In Q1 2026, Net Income rose 34.35% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$31.0 million (down 18.83% YoY), while the FY2025 annual figure was -$31.9 million, down 28.13% from the prior year.
- Net Income for Q1 2026 stood at -$2.0 million, up from -$22.6 million in the prior quarter.
- The five-year high for Net Income was -$187000.0 in Q3 2022, with the low at -$22.6 million in Q4 2025.
- The 5-year median for Net Income is -$2.6 million (2022), against an average of -$5.5 million.
- The sharpest annual moves came in 2022 and 2023: Net Income jumped 91.82% in 2022, then tumbled 3039.68% in 2023.
- GRI Bio's Net Income stood at -$5.2 million in 2022, then tumbled by 220.49% to -$16.5 million in 2023, then dropped by 12.64% to -$18.6 million in 2024, then slipped by 21.34% to -$22.6 million in 2025, then surged by 91.14% to -$2.0 million in 2026.
- Business Quant data shows GRI's Net Income at -$2.0 million in Q1 2026, -$22.6 million in Q4 2025, and -$3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | -1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.00 Mn |
| Dec 31, 2025 | -22.62 Mn |
| Sep 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -3.05 Mn |
| Dec 31, 2024 | -18.64 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -2.26 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -2.44 Mn |
| Jun 30, 2023 | -5.93 Mn |
| Mar 31, 2023 | -988,000.00 |
| Dec 31, 2022 | -5.16 Mn |
| Sep 30, 2022 | -187,000.00 |
| Jun 30, 2022 | -189,000.00 |
| Mar 31, 2022 | -2.64 Mn |
| Dec 31, 2021 | -10.11 Mn |
| Sep 30, 2021 | -1.26 Mn |
| Jun 30, 2021 | -2.31 Mn |